View Future GrowthNIBEC 과거 순이익 실적과거 기준 점검 3/6NIBEC은 연평균 16.4%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 수입이 15.2% 증가했습니다. 매출은 연평균 20.5%의 비율로 증가했습니다. NIBEC의 자기자본이익률은 15.5%이고 순이익률은 22.6%입니다.핵심 정보16.42%순이익 성장률-2.22%주당순이익(EPS) 성장률Biotechs 산업 성장률11.70%매출 성장률20.48%자기자본이익률15.52%순이익률22.56%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 19First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ₩6.43b (up 41% from 1Q 2023). Net income: ₩233.6m (up ₩393.9m from 1Q 2023). Profit margin: 3.6% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 19% per year.모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩12,200, the stock trades at a trailing P/E ratio of 19x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 13% over the past three years.New Risk • Jul 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩139.8b (US$96.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Jun 30Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 39% to ₩17,020. The fair value is estimated to be ₩22,099, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Jun 08Now 25% undervalued after recent price dropOver the last 90 days, the stock has fallen 41% to ₩17,430. The fair value is estimated to be ₩23,249, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.공고 • Mar 13NIBEC Co., Ltd., Annual General Meeting, Mar 30, 2026NIBEC Co., Ltd., Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 34, namsan-gil, jincheon-gun, chungcheongbuk-do, South Korea분석 기사 • Dec 11Revenues Not Telling The Story For NIBEC Co., Ltd. (KOSDAQ:138610) After Shares Rise 42%Despite an already strong run, NIBEC Co., Ltd. ( KOSDAQ:138610 ) shares have been powering on, with a gain of 42% in...분석 기사 • Nov 11Here's Why NIBEC (KOSDAQ:138610) Can Manage Its Debt ResponsiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Sep 26NIBEC Co., Ltd.'s (KOSDAQ:138610) Price Is Right But Growth Is Lacking After Shares Rocket 28%The NIBEC Co., Ltd. ( KOSDAQ:138610 ) share price has done very well over the last month, posting an excellent gain of...분석 기사 • Aug 08Is NIBEC (KOSDAQ:138610) Weighed On By Its Debt Load?KOSDAQ:A138610 1 Year Share Price vs Fair Value Explore NIBEC's Fair Values from the Community and select yours Howard...분석 기사 • May 29NIBEC Co., Ltd. (KOSDAQ:138610) Stock Rockets 41% As Investors Are Less Pessimistic Than ExpectedDespite an already strong run, NIBEC Co., Ltd. ( KOSDAQ:138610 ) shares have been powering on, with a gain of 41% in...New Risk • May 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.0% average weekly change).분석 기사 • Apr 10NIBEC Co., Ltd.'s (KOSDAQ:138610) Shares Climb 26% But Its Business Is Yet to Catch UpNIBEC Co., Ltd. ( KOSDAQ:138610 ) shareholders would be excited to see that the share price has had a great month...분석 기사 • Apr 09Is NIBEC (KOSDAQ:138610) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Mar 31New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩145.3b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩145.3b market cap, or US$98.7m).공고 • Mar 11NIBEC Co., Ltd., Annual General Meeting, Mar 28, 2025NIBEC Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 66, daehak-ro, jincheon-gun, chungcheongbuk-do, South KoreaNew Risk • Nov 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 18% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (9.4% increase in shares outstanding).분석 기사 • Nov 13More Unpleasant Surprises Could Be In Store For NIBEC Co., Ltd.'s (KOSDAQ:138610) Shares After Tumbling 34%NIBEC Co., Ltd. ( KOSDAQ:138610 ) shareholders won't be pleased to see that the share price has had a very rough month...분석 기사 • Oct 14Does NIBEC (KOSDAQ:138610) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Jun 18Is NIBEC (KOSDAQ:138610) Weighed On By Its Debt Load?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Reported Earnings • May 19First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ₩6.43b (up 41% from 1Q 2023). Net income: ₩233.6m (up ₩393.9m from 1Q 2023). Profit margin: 3.6% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 19% per year.분석 기사 • Mar 28NIBEC Co., Ltd.'s (KOSDAQ:138610) Share Price Not Quite Adding UpThere wouldn't be many who think NIBEC Co., Ltd.'s ( KOSDAQ:138610 ) price-to-sales (or "P/S") ratio of 12.5x is worth...New Risk • Jan 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 11% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (2.7% increase in shares outstanding).New Risk • Aug 30New major risk - Revenue and earnings growthEarnings have declined by 1.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.8% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).New Risk • Aug 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buying Opportunity • Aug 08Now 25% undervaluedOver the last 90 days, the stock is up 3.3%. The fair value is estimated to be ₩22,403, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has declined by 6.8%.New Risk • Jul 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩127.5b (US$97.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.공고 • Nov 24NIBEC Co., Ltd. announced that it has received KRW 25 billion in funding from a group of investorsOn November 22, 2022, NIBEC Co., Ltd. closed the transaction.분석 기사 • Apr 05NIBEC (KOSDAQ:138610) Has Debt But No Earnings; Should You Worry?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jan 04NIBEC (KOSDAQ:138610) Has Rewarded Shareholders With An Exceptional 411% Total Return On Their InvestmentLong term investing can be life changing when you buy and hold the truly great businesses. And we've seen some truly...Is New 90 Day High Low • Dec 07New 90-day high: ₩41,600The company is up 46% from its price of ₩28,400 on 08 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.Is New 90 Day High Low • Nov 10New 90-day high: ₩32,600The company is up 42% from its price of ₩23,000 on 12 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period.매출 및 비용 세부 내역NIBEC가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A138610 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Mar 2632,3437,2987,2075,61331 Dec 2532,7194,6428,7535,61330 Sep 2532,9603,13710,4524,07430 Jun 2533,577-2,43715,0884,07431 Mar 2523,739-11,06813,5244,07431 Dec 2424,550-9,32712,4134,07430 Sep 2422,812-7,84816,730030 Jun 2419,407-4,84311,853031 Mar 2417,578-5,89011,142031 Dec 2315,704-6,28410,490030 Sep 2316,213-11,6726,2305,36130 Jun 2317,493-8,1575,2585,36131 Mar 2318,878-5,1637,1574,40231 Dec 2221,670-3,76612,390030 Sep 2220,077-6789,19280630 Jun 2220,776-8468,0521,49231 Mar 2218,766-3,3405,2223,73531 Dec 2113,625-5,7404,6123,33330 Sep 2112,682-4,4193,9033,35630 Jun 219,383-5,5193,3202,93731 Mar 217,225-4,8342,5961,95731 Dec 206,357-3,6382,4111,53530 Sep 206,775-2,3142,0871,35430 Jun 207,971-1,8302,4821,35831 Mar 208,949-2,2352,6671,64631 Dec 199,287-2,7272,6821,68330 Sep 197,803-3,5892,9511,64030 Jun 196,664-4,0222,5881,45331 Mar 195,717-4,0212,5501,34731 Dec 185,208-4,1462,3951,20430 Sep 185,085-4,5562,3731,13430 Jun 185,326-4,1272,2371,06531 Mar 185,223-3,4062,01864431 Dec 176,303-2,5682,21064130 Sep 176,219-1,6832,39922830 Jun 175,890-2,3832,72429231 Mar 175,849-2,2802,83425631 Dec 164,804-3,0272,84825230 Sep 164,589-2,8232,53216930 Jun 164,600-2,3542,41310831 Mar 164,645-2,5862,41812031 Dec 154,174-2,4262,24811430 Sep 153,915-2,3172,23890양질의 수익: A138610는 고품질 수익을 보유하고 있습니다.이익 마진 증가: A138610는 과거에 흑자전환했습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A138610는 지난 5년 동안 흑자전환하며 연평균 16.4%의 수익 성장을 기록했습니다.성장 가속화: A138610는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.수익 대 산업: A138610는 지난해 흑자전환하여 지난 해 수익 성장률을 Biotechs 업계(22.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: A138610의 자본 수익률(15.5%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/16 23:47종가2026/08/14 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스NIBEC Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 19First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ₩6.43b (up 41% from 1Q 2023). Net income: ₩233.6m (up ₩393.9m from 1Q 2023). Profit margin: 3.6% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 19% per year.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩12,200, the stock trades at a trailing P/E ratio of 19x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 13% over the past three years.
New Risk • Jul 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩139.8b (US$96.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Jun 30Now 23% undervalued after recent price dropOver the last 90 days, the stock has fallen 39% to ₩17,020. The fair value is estimated to be ₩22,099, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Jun 08Now 25% undervalued after recent price dropOver the last 90 days, the stock has fallen 41% to ₩17,430. The fair value is estimated to be ₩23,249, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company has become profitable.
공고 • Mar 13NIBEC Co., Ltd., Annual General Meeting, Mar 30, 2026NIBEC Co., Ltd., Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 34, namsan-gil, jincheon-gun, chungcheongbuk-do, South Korea
분석 기사 • Dec 11Revenues Not Telling The Story For NIBEC Co., Ltd. (KOSDAQ:138610) After Shares Rise 42%Despite an already strong run, NIBEC Co., Ltd. ( KOSDAQ:138610 ) shares have been powering on, with a gain of 42% in...
분석 기사 • Nov 11Here's Why NIBEC (KOSDAQ:138610) Can Manage Its Debt ResponsiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Sep 26NIBEC Co., Ltd.'s (KOSDAQ:138610) Price Is Right But Growth Is Lacking After Shares Rocket 28%The NIBEC Co., Ltd. ( KOSDAQ:138610 ) share price has done very well over the last month, posting an excellent gain of...
분석 기사 • Aug 08Is NIBEC (KOSDAQ:138610) Weighed On By Its Debt Load?KOSDAQ:A138610 1 Year Share Price vs Fair Value Explore NIBEC's Fair Values from the Community and select yours Howard...
분석 기사 • May 29NIBEC Co., Ltd. (KOSDAQ:138610) Stock Rockets 41% As Investors Are Less Pessimistic Than ExpectedDespite an already strong run, NIBEC Co., Ltd. ( KOSDAQ:138610 ) shares have been powering on, with a gain of 41% in...
New Risk • May 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.0% average weekly change).
분석 기사 • Apr 10NIBEC Co., Ltd.'s (KOSDAQ:138610) Shares Climb 26% But Its Business Is Yet to Catch UpNIBEC Co., Ltd. ( KOSDAQ:138610 ) shareholders would be excited to see that the share price has had a great month...
분석 기사 • Apr 09Is NIBEC (KOSDAQ:138610) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Mar 31New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩145.3b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩145.3b market cap, or US$98.7m).
공고 • Mar 11NIBEC Co., Ltd., Annual General Meeting, Mar 28, 2025NIBEC Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 66, daehak-ro, jincheon-gun, chungcheongbuk-do, South Korea
New Risk • Nov 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 18% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (9.4% increase in shares outstanding).
분석 기사 • Nov 13More Unpleasant Surprises Could Be In Store For NIBEC Co., Ltd.'s (KOSDAQ:138610) Shares After Tumbling 34%NIBEC Co., Ltd. ( KOSDAQ:138610 ) shareholders won't be pleased to see that the share price has had a very rough month...
분석 기사 • Oct 14Does NIBEC (KOSDAQ:138610) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
분석 기사 • Jun 18Is NIBEC (KOSDAQ:138610) Weighed On By Its Debt Load?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Reported Earnings • May 19First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ₩6.43b (up 41% from 1Q 2023). Net income: ₩233.6m (up ₩393.9m from 1Q 2023). Profit margin: 3.6% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 19% per year.
분석 기사 • Mar 28NIBEC Co., Ltd.'s (KOSDAQ:138610) Share Price Not Quite Adding UpThere wouldn't be many who think NIBEC Co., Ltd.'s ( KOSDAQ:138610 ) price-to-sales (or "P/S") ratio of 12.5x is worth...
New Risk • Jan 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 11% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (2.7% increase in shares outstanding).
New Risk • Aug 30New major risk - Revenue and earnings growthEarnings have declined by 1.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.8% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
New Risk • Aug 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buying Opportunity • Aug 08Now 25% undervaluedOver the last 90 days, the stock is up 3.3%. The fair value is estimated to be ₩22,403, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Earnings per share has declined by 6.8%.
New Risk • Jul 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩127.5b (US$97.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
공고 • Nov 24NIBEC Co., Ltd. announced that it has received KRW 25 billion in funding from a group of investorsOn November 22, 2022, NIBEC Co., Ltd. closed the transaction.
분석 기사 • Apr 05NIBEC (KOSDAQ:138610) Has Debt But No Earnings; Should You Worry?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
분석 기사 • Jan 04NIBEC (KOSDAQ:138610) Has Rewarded Shareholders With An Exceptional 411% Total Return On Their InvestmentLong term investing can be life changing when you buy and hold the truly great businesses. And we've seen some truly...
Is New 90 Day High Low • Dec 07New 90-day high: ₩41,600The company is up 46% from its price of ₩28,400 on 08 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.
Is New 90 Day High Low • Nov 10New 90-day high: ₩32,600The company is up 42% from its price of ₩23,000 on 12 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period.